{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["61(7)"],"submitter":["Cetin D"],"pubmed_abstract":["<i>Background and Objectives</i>: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly used in type 2 diabetes (T2D) due to their cardiorenal benefits and weight-lowering effects. However, concerns have emerged regarding their potential adverse impact on lean mass and muscle strength particularly in patients at risk for sarcopenia. This study aimed to evaluate the effects of empagliflozin on skeletal muscle mass. Secondary objectives were to assess changes in glycemic control, body weight, fat mass and handgrip strength. <i>Materials and Methods</i>: In this 24-week real-world observational study, 31 adult patients with T2D were assigned to either empagliflozin or non-SGLT2i treatment groups. Patients did not receive a high-protein diet, a resistance exercise program or any o"],"journal":["Medicina (Kaunas, Lithuania)"],"pagination":["1152"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12299443"],"repository":["biostudies-literature"],"pubmed_title":["Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study."],"pmcid":["PMC12299443"],"pubmed_authors":["Komac O","Yetisken M","Cetin D","Guney E","Bilgili E"],"additional_accession":[]},"is_claimable":false,"name":"Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study.","description":"<i>Background and Objectives</i>: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly used in type 2 diabetes (T2D) due to their cardiorenal benefits and weight-lowering effects. However, concerns have emerged regarding their potential adverse impact on lean mass and muscle strength particularly in patients at risk for sarcopenia. This study aimed to evaluate the effects of empagliflozin on skeletal muscle mass. Secondary objectives were to assess changes in glycemic control, body weight, fat mass and handgrip strength. <i>Materials and Methods</i>: In this 24-week real-world observational study, 31 adult patients with T2D were assigned to either empagliflozin or non-SGLT2i treatment groups. Patients did not receive a high-protein diet, a resistance exercise program or any o","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jun","modification":"2025-08-30T03:10:39.393Z","creation":"2025-08-30T03:05:19.99Z"},"accession":"S-EPMC12299443","cross_references":{"pubmed":["40731782"],"doi":["10.3390/medicina61071152"]}}